SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
Targeting TGFβ in pancreatic cancers that are deficient in canonical TGFβ signaling could provide a therapeutic strategy to enhance standard and immune therapy approaches for a substantial population of pancreatic cancer patients.
Authors
- Jason E. Toombs (ORCID: https://orcid.org/0000-0002-9264-3761)
- Aatur Dilip Singhi (ORCID: https://orcid.org/0000-0003-3930-7096)
- Jill M. Westcott
- Gilbert Z. Murimwa (ORCID: https://orcid.org/0000-0001-7948-0980)
- Jason B. Fleming (ORCID: https://orcid.org/0000-0002-8796-5627)
- Cecilia G. Ethun
- Huocong Huang (ORCID: https://orcid.org/0000-0002-6345-4566)
- Alexandra F. Tassielli (ORCID: https://orcid.org/0009-0009-1445-8227)
- Dina Alzhanova (ORCID: https://orcid.org/0000-0001-5557-6726)
- Ruifan Dai
- N. Williams
- Luis Nivelo (ORCID: https://orcid.org/0000-0002-4943-1827)
- Rolf A. Brekken (ORCID: https://orcid.org/0000-0003-2704-2377)
- Henry K. Fleming
- Francisca Beato (ORCID: https://orcid.org/0009-0003-0147-4013)
- Zeynep Yazgan (ORCID: https://orcid.org/0009-0002-6902-3692)
- Francesca Rossi (ORCID: https://orcid.org/0000-0001-7327-6364)
- Amir Mohammadi (ORCID: https://orcid.org/0000-0002-3555-0358)
Institutions
- Babraham Institute (GB)
- University of Miami (US)
- University of Pittsburgh (US)
- Moffitt Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1158/0008-5472.can-24-1970
- Citations
- 5
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 5.23